CANTA (CANTA) News
Follow CANTA (CANTA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cantargia AB (publ) (CANTA) Preclinical Data Back Nadunolimab+RASi, Phase 1b/2a Planned
Cantargia reported preclinical data from Fred Hutch showing nadunolimab plus a RAS inhibitor reduced tumor burden and immune suppression in PDAC models, supporting a planned Phase 1b/2a trial.Material DetailsContext by A
NEWS | Sep 30, 2026, 05:00 AM UTC
L
Cantargia to present at Investing in Life Science on September 22
Cantargia will present to specialist life science investors and potential strategic partners at the 4th edition of Investing in Life Science on September 22 in Stockholm. Cantargia CEO Hilde Steineger will present.
MACRO | Sep 10, 2026, 07:01 AM UTC
L
CANTA - Cantargia to Participate in Upcoming Investor Conferences
CANTA - Cantargia to Participate in Upcoming Investor Conferences
EQUITY | Aug 28, 2026, 09:20 AM UTC
L
Cantargia to participate in upcoming investor conferences
Cantargia plans to take part in upcoming investor conferences.
EQUITY | Aug 28, 2026, 09:00 AM UTC
L
Cantargia rasonque approval clears path to Phase Ib for nadunolimab
Cantargia’s rasonque approval clears the path for nadunolimab Phase Ib.
EQUITY | Aug 28, 2026, 08:36 AM UTC
L
Cantargia publishes half-year report 2026
Cantargia publishes its half-year report 2026, with no additional financial figures, guidance details, or catalyst supplied in the alert.
EQUITY | Aug 19, 2026, 05:15 AM UTC
L
CANTA - Cantargia to Host Q2 2026 Interim Results Conference Call
CANTA - Cantargia to Host Q2 2026 Interim Results Conference Call
EQUITY | Aug 04, 2026, 08:20 AM UTC
L
Cantargia Announces Share Changes
Cantargia updates share and vote numbers
EQUITY | Jul 31, 2026, 08:20 AM UTC